Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience

I. Gauthier, K. Ding, T. Winton, F. A. Shepherd, Robert B Livingston, D. H. Johnson, J. R. Rigas, M. Whitehead, B. Graham, L. Seymour

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Cisplatin-induced anemia may correlate with adverse events, poor quality of life (QoL), decreased adjuvant chemotherapy (ACT) dose intensity, shorter relapse-free survival (RFS) or overall survival (OS). Methods: The JBR.10 trial demonstrated significantly longer survival with adjuvant cisplatin and vinorelbine (n = 242) compared to observation (n = 240) in patients with resected NSCLC [Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2640-2]. This exploratory analysis evaluates the predictive value of baseline (in all patients) and during-treatment (in ACT arm only) hemoglobin (Hb) levels on OS and RFS when adjusted for prognostic factors. Baseline (in all patients) and during treatment (in ACT arm only) Hb levels were also correlated with adverse events, QoL, morbidity and ACT dose intensity. Results: Baseline Hb did not predict RFS or OS. However, there was a trend to shorter OS (p = 0.1) when baseline Hb was <120 g/L. Lower baseline Hb predicted increased hospitalization (p = 0.04) and worse QoL (SOB item, p = 0.03) but had no impact on adverse events or dose intensity. There was a trend to longer RFS (p = 0.08) in patients with lower nadir during-treatment Hb and to longer OS (p = 0.06) and RFS (p = 0.08) in patients with maximum during-treatment Hb drop >30% that was not maintained when ACT dose intensity was included in the model. Maximum during-treatment Hb drop >30% correlated with increased lethargy (p = 0.003) and worse QoL (fatigue item, p = 0.07). Conclusions: Lower baseline and during-treatment Hb levels seem associated with poorer QoL, fatigue and increased hospitalization. There is a trend for shorter OS in patients with lower baseline Hb levels.

Original languageEnglish (US)
Pages (from-to)357-363
Number of pages7
JournalLung Cancer
Volume55
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Hemoglobins
Survival
Quality of Life
Cisplatin
Recurrence
Fatigue
Observation
Lethargy
Therapeutics
Anemia
Hospitalization
Morbidity

Keywords

  • Adjuvant chemotherapy
  • Clinical outcomes
  • Hb levels
  • NSCLC

ASJC Scopus subject areas

  • Oncology

Cite this

Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer : The JBR.10 trial experience. / Gauthier, I.; Ding, K.; Winton, T.; Shepherd, F. A.; Livingston, Robert B; Johnson, D. H.; Rigas, J. R.; Whitehead, M.; Graham, B.; Seymour, L.

In: Lung Cancer, Vol. 55, No. 3, 03.2007, p. 357-363.

Research output: Contribution to journalArticle

Gauthier, I, Ding, K, Winton, T, Shepherd, FA, Livingston, RB, Johnson, DH, Rigas, JR, Whitehead, M, Graham, B & Seymour, L 2007, 'Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience', Lung Cancer, vol. 55, no. 3, pp. 357-363. https://doi.org/10.1016/j.lungcan.2006.10.021
Gauthier, I. ; Ding, K. ; Winton, T. ; Shepherd, F. A. ; Livingston, Robert B ; Johnson, D. H. ; Rigas, J. R. ; Whitehead, M. ; Graham, B. ; Seymour, L. / Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer : The JBR.10 trial experience. In: Lung Cancer. 2007 ; Vol. 55, No. 3. pp. 357-363.
@article{771e75a5eeac47f3ac158ed532b9fb0a,
title = "Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience",
abstract = "Background: Cisplatin-induced anemia may correlate with adverse events, poor quality of life (QoL), decreased adjuvant chemotherapy (ACT) dose intensity, shorter relapse-free survival (RFS) or overall survival (OS). Methods: The JBR.10 trial demonstrated significantly longer survival with adjuvant cisplatin and vinorelbine (n = 242) compared to observation (n = 240) in patients with resected NSCLC [Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2640-2]. This exploratory analysis evaluates the predictive value of baseline (in all patients) and during-treatment (in ACT arm only) hemoglobin (Hb) levels on OS and RFS when adjusted for prognostic factors. Baseline (in all patients) and during treatment (in ACT arm only) Hb levels were also correlated with adverse events, QoL, morbidity and ACT dose intensity. Results: Baseline Hb did not predict RFS or OS. However, there was a trend to shorter OS (p = 0.1) when baseline Hb was <120 g/L. Lower baseline Hb predicted increased hospitalization (p = 0.04) and worse QoL (SOB item, p = 0.03) but had no impact on adverse events or dose intensity. There was a trend to longer RFS (p = 0.08) in patients with lower nadir during-treatment Hb and to longer OS (p = 0.06) and RFS (p = 0.08) in patients with maximum during-treatment Hb drop >30{\%} that was not maintained when ACT dose intensity was included in the model. Maximum during-treatment Hb drop >30{\%} correlated with increased lethargy (p = 0.003) and worse QoL (fatigue item, p = 0.07). Conclusions: Lower baseline and during-treatment Hb levels seem associated with poorer QoL, fatigue and increased hospitalization. There is a trend for shorter OS in patients with lower baseline Hb levels.",
keywords = "Adjuvant chemotherapy, Clinical outcomes, Hb levels, NSCLC",
author = "I. Gauthier and K. Ding and T. Winton and Shepherd, {F. A.} and Livingston, {Robert B} and Johnson, {D. H.} and Rigas, {J. R.} and M. Whitehead and B. Graham and L. Seymour",
year = "2007",
month = "3",
doi = "10.1016/j.lungcan.2006.10.021",
language = "English (US)",
volume = "55",
pages = "357--363",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer

T2 - The JBR.10 trial experience

AU - Gauthier, I.

AU - Ding, K.

AU - Winton, T.

AU - Shepherd, F. A.

AU - Livingston, Robert B

AU - Johnson, D. H.

AU - Rigas, J. R.

AU - Whitehead, M.

AU - Graham, B.

AU - Seymour, L.

PY - 2007/3

Y1 - 2007/3

N2 - Background: Cisplatin-induced anemia may correlate with adverse events, poor quality of life (QoL), decreased adjuvant chemotherapy (ACT) dose intensity, shorter relapse-free survival (RFS) or overall survival (OS). Methods: The JBR.10 trial demonstrated significantly longer survival with adjuvant cisplatin and vinorelbine (n = 242) compared to observation (n = 240) in patients with resected NSCLC [Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2640-2]. This exploratory analysis evaluates the predictive value of baseline (in all patients) and during-treatment (in ACT arm only) hemoglobin (Hb) levels on OS and RFS when adjusted for prognostic factors. Baseline (in all patients) and during treatment (in ACT arm only) Hb levels were also correlated with adverse events, QoL, morbidity and ACT dose intensity. Results: Baseline Hb did not predict RFS or OS. However, there was a trend to shorter OS (p = 0.1) when baseline Hb was <120 g/L. Lower baseline Hb predicted increased hospitalization (p = 0.04) and worse QoL (SOB item, p = 0.03) but had no impact on adverse events or dose intensity. There was a trend to longer RFS (p = 0.08) in patients with lower nadir during-treatment Hb and to longer OS (p = 0.06) and RFS (p = 0.08) in patients with maximum during-treatment Hb drop >30% that was not maintained when ACT dose intensity was included in the model. Maximum during-treatment Hb drop >30% correlated with increased lethargy (p = 0.003) and worse QoL (fatigue item, p = 0.07). Conclusions: Lower baseline and during-treatment Hb levels seem associated with poorer QoL, fatigue and increased hospitalization. There is a trend for shorter OS in patients with lower baseline Hb levels.

AB - Background: Cisplatin-induced anemia may correlate with adverse events, poor quality of life (QoL), decreased adjuvant chemotherapy (ACT) dose intensity, shorter relapse-free survival (RFS) or overall survival (OS). Methods: The JBR.10 trial demonstrated significantly longer survival with adjuvant cisplatin and vinorelbine (n = 242) compared to observation (n = 240) in patients with resected NSCLC [Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352(25):2640-2]. This exploratory analysis evaluates the predictive value of baseline (in all patients) and during-treatment (in ACT arm only) hemoglobin (Hb) levels on OS and RFS when adjusted for prognostic factors. Baseline (in all patients) and during treatment (in ACT arm only) Hb levels were also correlated with adverse events, QoL, morbidity and ACT dose intensity. Results: Baseline Hb did not predict RFS or OS. However, there was a trend to shorter OS (p = 0.1) when baseline Hb was <120 g/L. Lower baseline Hb predicted increased hospitalization (p = 0.04) and worse QoL (SOB item, p = 0.03) but had no impact on adverse events or dose intensity. There was a trend to longer RFS (p = 0.08) in patients with lower nadir during-treatment Hb and to longer OS (p = 0.06) and RFS (p = 0.08) in patients with maximum during-treatment Hb drop >30% that was not maintained when ACT dose intensity was included in the model. Maximum during-treatment Hb drop >30% correlated with increased lethargy (p = 0.003) and worse QoL (fatigue item, p = 0.07). Conclusions: Lower baseline and during-treatment Hb levels seem associated with poorer QoL, fatigue and increased hospitalization. There is a trend for shorter OS in patients with lower baseline Hb levels.

KW - Adjuvant chemotherapy

KW - Clinical outcomes

KW - Hb levels

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=33847283017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847283017&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.10.021

DO - 10.1016/j.lungcan.2006.10.021

M3 - Article

C2 - 17141357

AN - SCOPUS:33847283017

VL - 55

SP - 357

EP - 363

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -